Additional Information

Description

Cimerli (ranibizumab-eqrn) is a vascular endothelial growth factor (VEGF) inhibitor used for the treatment of retinal vascular disorders. It functions by binding to VEGF-A, preventing its interaction with VEGF receptors on endothelial cells, thereby inhibiting abnormal blood vessel growth and reducing vascular permeability. This mechanism is essential in managing neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), and macular edema following retinal vein occlusion (RVO).

Each single-dose vial contains 0.3 mg/0.05 mL of ranibizumab-eqrn in a sterile, preservative-free aqueous solution. The formulation is designed for intravitreal injection by a healthcare professional under aseptic conditions. The solution must be stored under refrigeration between 2°C and 8°C and protected from light.

Common adverse effects include conjunctival hemorrhage, eye pain, vitreous floaters, and increased intraocular pressure. Serious complications include endophthalmitis, retinal detachment, and arterial thromboembolic events. Patients require regular monitoring for signs of infection, inflammation, or vision changes.